Clinical data | |
---|---|
Trade names | Clinoril |
AHFS/Drugs.com | Monograph |
MedlinePlus | a681037 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Approximately 90% (Oral) |
Metabolism | ? |
Elimination half-life | 7.8 hours, metabolites up to 16.4 hours |
Excretion | Renal (50%) and fecal (25%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.048.909 |
Chemical and physical data | |
Formula | C20H17FO3S |
Molar mass | 356.41 g·mol−1 |
3D model (JSmol) | |
Melting point | 182 to 185 °C (360 to 365 °F) (decomp.) |
| |
| |
(what is this?) (verify) |
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed as Clinoril. Imbaral (not to be confused with mebaral) is another name for this drug. Its name is derived from sul(finyl)+ ind(ene)+ ac(etic acid) It was patented in 1969 and approved for medical use in 1976.[1]